SEARCH

SEARCH BY CITATION

References

  • 1
    Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011; 140: 124-131.
  • 2
    Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander_Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 2467-2474.
    Direct Link:
  • 3
    Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011; 34: 274-285.
  • 4
    Yamanaka H, Genjida K, Yokota K, Taketani Y, Morita K, Miyamoto KI, et al. Daily pattern of energy metabolism in cirrhosis. Nutrition 1999; 15: 749-754.
  • 5
    van der Poorten D, Samer CF, Ramezani_Moghadam M, Coulter S, Kacevska M, Schrijnders D, et al. Hepatic fat loss in advanced NASH: are alterations in serum adiponectin the cause? HEPATOLOGY 2013;57:21802188.
  • 6
    Pajvani UB, Du X, Combs TP, Berg AH, Rajala MW, Schulthess T, et al. Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications for metabolic regulation and bioactivity. J Biol Chem 2003; 278: 9073-9085.
  • 7
    Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S, et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003; 423: 762-769.
  • 8
    Yamauchi T, Nio Y, Maki T, Kobayashi M, Takazawa T, Iwabu M, et al. Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med 2007; 13: 332-339.
  • 9
    Liu Q, Yuan B, Lo KA, Patterson HC, Sun Y, Lodish HF. Adiponectin regulates expression of hepatic genes critical for glucose and lipid metabolism. Proc Natl Acad Sci U S A 2012; 109: 14568-14573.
  • 10
    Pagano C, Soardo G, Esposito W, Fallo F, Basan L, Donnini D, et al. Plasma adiponectin is decreased in nonalcoholic fatty liver disease. Eur J Endocrinol 2005; 152: 113-118.
  • 11
    Castle JC, Hara Y, Raymond CK, Garrett_Engele P, Ohwaki K, Kan Z, et al. ACC2 is expressed at high levels in human white adipose and has an isoform with a novel N-terminus [corrected]. PLoS ONE 2009; 4: e4369.
  • 12
    Kaser S, Moschen A, Cayon A, Kaser A, Crespo J, Pons_Romero F, et al. Adiponectin and its receptors in non-alcoholic steatohepatitis. Gut 2005; 54: 117-121.
  • 13
    Nagaya T, Tanaka N, Suzuki T, Sano K, Horiuchi A, Komatsu M, et al. Down-regulation of SREBP-1c is associated with the development of burned-out NASH. J Hepatol 2010; 53: 724-731.
  • 14
    Tietge UJ, Böker KH, Manns MP, Bahr MJ Elevated circulating adiponectin levels in liver cirrhosis are associated with reduced liver function and altered hepatic hemodynamics. Am J Physiol Endocrinol Metab 2004; 287: E82-E89.
  • 15
    Tacke F, Wüstefeld T, Horn R, Luedde T, Srinivas Rao A, Manns MP, et al. High adiponectin in chronic liver disease and cholestasis suggests biliary route of adiponectin excretion in vivo. J Hepatol 2005; 42: 666-673.
  • 16
    Balmer ML, Joneli J, Schoepfer A, Stickel F, Thormann W, Dufour JF, et al. Significance of serum adiponectin levels in patients with chronic liver disease. Clin Sci (Lond) 2010; 119: 431-436.
  • 17
    Aranha MM, Cortez_Pinto H, Costa A, da Silva IB, Camilo ME, de Moura MC, et al. Bile acid levels are increased in the liver of patients with steatohepatitis. Eur J Gastroenterol Hepatol 2008; 20: 519-525.
  • 18
    Trauner M, Halilbasic E. Nuclear receptors as new perspective for the management of liver diseases. Gastroenterology 2011; 140: 1120-1125.
  • 19
    Trauner M, Claudel T, Fickert P, Moustafa T, Wagner M. Bile acids as regulators of hepatic lipid and glucose metabolism. Dig Dis 2010; 28: 220-224.
  • 20
    Maruyama T, Miyamoto Y, Nakamura T, Tamai Y, Okada H, Sugiyama E, et al. Identification of membrane-type receptor for bile acids (M-BAR). Biochem Biophys Res Commun 2002; 298: 714-719.
  • 21
    Kawamata Y, Fujii R, Hosoya M, Harada M, Yoshida H, Miwa M, et al. A G protein-coupled receptor responsive to bile acids. J Biol Chem 2003; 278: 9435-9440.
  • 22
    Makishima M, Okamoto AY, Repa JJ, Tu H, Learned RM, Luk A, et al. Identification of a nuclear receptor for bile acids. Science 1999; 284: 1362-1365.
  • 23
    Parks DJ, Blanchard SG, Bledsoe RK, Chandra G, Consler TG, Kliewer SA, et al. Bile acids: natural ligands for an orphan nuclear receptor. Science 1999; 284: 1365-1368.
  • 24
    Wang H, Chen J, Hollister K, Sowers LC, Forman BM. Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol Cell 1999; 3: 543-553.
  • 25
    Zhang Y, Kast-Woelbern HR, Edwards PA. Natural structural variants of the nuclear receptor farnesoid X receptor affect transcriptional activation. J Biol Chem 2003; 278: 104-110.
  • 26
    Hascoet S, Elbaz M, Bongard V, Bouisset F, Verdier C, Vindis C, et al. Adiponectin and long-term mortality in coronary artery disease participants and controls. Arterioscler Thromb Vasc Biol 2013; 33: e19-e29.
  • 27
    Van Berendoncks AM, Garnier A, Beckers P, Hoymans VY, Possemiers N, Fortin D, et al. Functional adiponectin resistance at the level of the skeletal muscle in mild to moderate chronic heart failure. Circ Heart Fail 2010; 3: 185-194.
  • 28
    Einarsson C, Hillebrant CG, Axelson M. Effects of treatment with deoxycholic acid and chenodeoxycholic acid on the hepatic synthesis of cholesterol and bile acids in healthy subjects. HEPATOLOGY 2001; 33: 1189-1193.
  • 29
    Min HK, Kapoor A, Fuchs M, Mirshahi F, Zhou H, Maher J, et al. Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease. Cell Metab 2012; 15: 665-674.
  • 30
    Stenman LK, Holma R, Korpela R. High-fat-induced intestinal permeability dysfunction associated with altered fecal bile acids. World J Gastroenterol 2012; 18: 923-929.
  • 31
    Miele L, Valenza V, La Torre G, Montalto M, Cammarota G, Ricci R, et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. HEPATOLOGY 2009; 49: 1877-1887.
  • 32
    Ohashi K, Parker JL, Ouchi N, Higuchi A, Vita JA, Gokce N, et al. Adiponectin promotes macrophage polarization toward an anti-inflammatory phenotype. J Biol Chem 2010; 285: 6153-6160.
  • 33
    Tullin S, Sams A, Brandt J, Dahl K, Gong W, Jeppesen CB, et al. Recombinant adiponectin does not lower plasma glucose in animal models of type 2 diabetes. PLoS ONE 2012; 7: e44270.